Table 1:
Demographics and clinical characteristics of rheumatic disease patients with COVID-19
| Time period | ||||||
|---|---|---|---|---|---|---|
| Early COVID-19 | Early treatment | Early vaccination | Additional vaccination and Delta wave | Omicron wave | ||
| Overall (n = 1449) | March 1 2020 - June 30 2020 (n = 261) | July 1 2020 - Jan 31 2021 (n = 492) | Feb 1 2021 - June 30 2021 (n = 123) | July 1 2021 - Dec 16 2021 (n = 172) | Dec 17 2021 - Jan 31 2022 (n = 401) | |
| Age, years (mean ± SD) | 58.4 (17.5) | 63.1 (16.6) | 59.3 (17.0) | 55.5 (16.9) | 56.8 (17.7) | 54.2 (17.6) |
| Female sex, n (%) | 1090 (75.2%) | 196 (75.1%) | 370 (75.2%) | 90 (73.2%) | 111 (64.5%) | 323 (80.5%) |
| Race, n (%) | ||||||
| White | 1035 (71.4%) | 154 (59.0%) | 353 (71.7%) | 93 (75.6%) | 136 (79.1%) | 299 (74.6%) |
| Black | 162 (11.2%) | 52 (19.9%) | 50 (10.2%) | 15 (12.2%) | 11 (6.4%) | 34 (8.5%) |
| Asian, Hawaiian or Pacific Islander | 52 (3.6%) | 9 (3.4%) | 19 (3.9%) | 6 (4.9%) | 7 (4.1%) | 11 (2.7%) |
| Other or unknown | 200 (13.8%) | 46 (17.6%) | 70 (14.2%) | 9 (7.3%) | 18 (10.5%) | 57 (14.2%) |
| Hispanic ethnicity, n (%) | 67 (4.6%) | 13 (5.0%) | 31 (6.3%) | 5 (4.1%) | 4 (2.3%) | 14 (3.5%) |
| Comorbidities, n (%) | ||||||
| Hypertension | 635 (43.8%) | 154 (59.0%) | 220 (44.7%) | 49 (39.8%) | 63 (36.6%) | 149 (37.2%) |
| Diabetes Mellitus | 234 (16.1%) | 61 (23.4%) | 92 (18.7%) | 20 (16.3%) | 20 (11.6%) | 41 (10.2%) |
| Obesity | 427 (29.5%) | 92 (35.2%) | 156 (31.7%) | 49 (39.8%) | 35 (20.3%) | 95 (23.7%) |
| Cardiovascular disease | 210 (14.5%) | 62 (23.8%) | 72 (14.6%) | 15 (12.2%) | 20 (11.6%) | 41 (10.2%) |
| Obstructive lung disease | 310 (21.4%) | 73 (28.0%) | 109 (22.2%) | 25 (20.3%) | 31 (18.0%) | 72 (18.0%) |
| Interstitial lung disease | 81 (6.0%) | 17 (6.5%) | 25 (5.1%) | 8 (6.5%) | 9 (5.2%) | 22 (5.5%) |
| Vaccination status, n (%) | ||||||
| Unvaccinated or pre-vaccine | 938 (64.7%) | 261 (100%) | 492 (100%) | 102 (82.9%) | 40 (23.3%) | 43 (10.7%) |
| Partially vaccinated | 50 (3.5%) | 0 (0%) | 0 (0%) | 19 (15.4%) | 14 (8.1%) | 17 (4.2%) |
| Two doses mRNA or one dose J&J | 228 (15.7%) | 0 (0%) | 0 (0%) | 2 (1.6%) | 90 (52.3%) | 136 (33.9%) |
| Additional doses | 233 (16.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 28 (16.3%) | 205 (51.1%) |
| SARS-CoV2 diagnosis method, n (%) | ||||||
| PCR | 1126 (77.7%) | 246 (94.3%) | 426 (86.6%) | 100 (81.3%) | 129 (75.0%) | 225 (56.1%) |
| Antigen/rapid test | 123 (8.5%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.6%) | 122 (30.4%) |
| Other or unknown | 200 (13.8%) | 15 (5.7%) | 66 (13.4%) | 23 (18.7%) | 42 (24.4%) | 54 (13.5%) |
COVID-19, coronavirus disease 2019; SD, standard deviation; mRNA, messenger ribonucleic acid; J&J, Johnson and Johnson / Janssen; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; PCR, polymerase chain reaction